| HHV-8 Serocon/T (%)N = 21/181 | COR (95%C.I.) | AOR (95% C.I.) | P |
---|---|---|---|---|
Gender | Â | Â | Â | Â |
Females | - | Â | Â | Â |
Males | 21/181 (11.2) | N.A. | N.A. | Â |
Age **(years) | Â | Â | Â | Â |
< 25 | 1/7 (14.3) | 1.0 | 1.0 | Â |
25–35 | 9/71 (12.7) | 0.87 (0.10–8.10) | 0.69 (0.06–7.13) | .758 |
> 35 | 11/103 (10.7) | 0.72 (0.10–7.52) | 0.53 (0.05–5.70) | .599 |
STI during follow-up | Â | Â | Â | Â |
None | 16/154(10.4) | 1.0 | 1.0 | Â |
Any | 5/27 (18.5) | 1.96 (0.51–6.35) | 1.80 (0.52–7.96) | . 480 |
   Other STI ^ | 1/10 (10.0) | 0.96 (0.02–7.76) | 1.13 (0.13–9.96) | .913 |
   Syphilis | 1/7 (14.3) | 1.44 (0.03–13.05) | 1.47 (0.15–14.13) | .739 |
   Gonorrhea | 3/10 (30.0) | 3.70 (0.56–18.11) | 3.20 (0.67–15.36) | .146 |
HIV-1 during follow-up | Â | Â | Â | Â |
Non-seroconverters | 20/175(11.4) | 1.0 | 1.0 | Â |
Seroconverters | 1/6 (16.7) | 1.55(0.03–14.87) | 1.56 (0.16–15.69) | .704 |
No. sexual partners during follow-up | Â | Â | Â | Â |
< 3 | 4/55(7.3) | 1.0 | 1.0 | Â |
3–5 | 4/43(9.3) | 1.30 (0.31–5.56) | 1.41 (0.32–6.13) | .647 |
6–10 | 4/36 (11.1) | 1.59 (0.37–6.83) | 1.50 (0.32–6.82) | .601 |
> 10 | 9/47 (19.1) | 3.02 (0.86–10.54) | 3.32 (0.89–12.46) | .075 |